Why Outlook Therapeutics, Inc.’s (OTLK) Stock Is Down 5.62%
As of Monday, October 26, Outlook Therapeutics, Inc.’s OTLK share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Commentary & Analysis
Why Outlook Therapeutics, Inc.’s (OTLK) Stock Is Down 6.90%
As of Friday, October 23, Outlook Therapeutics, Inc.’s OTLK share price has dipped by 6.90%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Outlook Therapeutics, Inc.’s (OTLK) Stock Is Up 7.50%
As of Wednesday, October 21, Outlook Therapeutics, Inc.’s OTLK share price has surged by 7.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Outlook Therapeutics, Inc.’s (OTLK) Stock Is Up 6.69%
As of Tuesday, October 20, Outlook Therapeutics, Inc.’s OTLK share price has surged by 6.69%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Outlook Therapeutics, Inc.’s (OTLK) Stock Is Up 5.30%
As of Thursday, October 15, Outlook Therapeutics, Inc.’s OTLK share price has surged by 5.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | OTLK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $131.8 | $232.8 | 24% |
|
| Shares Out (Mil) | 136.7 | 53.4 | 69% |
|
| Institutional Ownership | 98.1% | 92.9% | 77% |
|
| Float (Mil) | 176.6 | 41.2 | 71% |
|
| Beta | 0.75 | 0.96 | 44% |
|
| Avg Daily Volume (000s) | 3,265 | 490 | 88% |
|
| Price Change (52-week) |
(59.6%) | 48.2% | 16% |
|
| Growth | OTLK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (12.1%) | (10.1%) | 27% |
|
| EPS (5yr) | 33.2% | 15.8% | 84 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.7%) | (15.7%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 3 | |
| Current EPS | ($0.075) | ($0.435) | ($0.120) | |
| Month Ago EPS | ($0.075) | ($0.435) | ($0.120) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.055) | ($0.493) | ($0.160) | |
| Year/Year Chg | (49.7%) | (75.8%) | (118.4%) | |
| Financials | OTLK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($61) | ($44) | 15% |
|
| EPS (TTM) | ($0.748) | ($1.600) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($33) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $166 | $174 | 25% |
|
| Valuation | OTLK | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.22 | na |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OTLK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 195.6% | 66.9% | 100% |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (251.7%) | (47.3%) | 1% |
|
| ROE | 256.9% | (53.3%) | 99% |
|
| Liabilities to Assets | 139.7% | 29.4% | 98% |
|
| F-Score | 3 | 2 | 18% |
|
Outlook Therapeutics, Inc. did not pass any screens on 10/28/2026.
